AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$CATX

Lantheus Holdings, Inc. sold $246K of CATX

Lantheus Holdings, Inc. sold 78,145 shares of Perspective Therapeutics, Inc. (CATX) at $3.14 ($0.25M total) on 2026-08-31.

Original reporting
SEC EDGAR · Lantheus Holdings, Inc.
Published Sep 2, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
low confidence
Mentioned
$CATX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The disclosed sale represents a modest reduction in a large insider position, unlikely to move the stock materially.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The sale could be a routine liquidity event unrelated to company fundamentals.

Relevance 4/10Novelty 4/10Timing: filing date 2026-09-02

Background

Perspective Therapeutics (NASDAQ: CATX) is a clinical‑stage biotech. Lantheus Holdings reported a direct sale of shares under a Form 4 filing.

Company-level read

Ticker impact

$CATXNeutralLow confidence
Context

SEC Form 4 shows Lantheus sold 78,145 Perspective Therapeutics shares for $245.6K on 2026-08-31.

Expected impact

Limited short‑term impact; price likely unchanged.

Evidence & confidence

The transaction is small relative to total float and does not constitute a material change in ownership.

Market effects

Sector

Minimal; insider activity does not affect broader biotech sector.

Regional

None; transaction is US‑listed but small.

Global

None

Counterpoint

What could challenge this read

Some traders may view any insider sell as a bearish signal and short the stock.

Key entities

  • company
    Perspective Therapeutics, Inc.

    Biotech issuer of the shares sold.

  • insider
    Lantheus Holdings, Inc.

    Reporter of the Form 4 and 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CATX insider trading history →

Related articles

OCT 8
$CATXMedAI 8/10

Perspective Granted FDA Fast Track for PSV359 in FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359, an investigational FAP-targeted alpha therapy, to treat adult patients with locally advanced or metastatic FAP-positive solitary fibrous tumors. The drug is currently in a Phase 1/2a study, with early human imaging showing promising results. Fast Track designation may expedite development and review processes.

tradingview.com1 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or…

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors SEATTLE, Oct. 08, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Co

SEC EDGAR 8-K2 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track Designation for PSV359, a treatment for FAP-positive solitary fibrous tumors. The therapy targets FAP-α, a protein linked to aggressive cancers, with limited current treatment options. The FDA program aims to expedite development and review for serious conditions with unmet medical needs.

globenewswire.com2 min
OCT 7
$CATXLowAI 8/10

Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors

Perspective Therapeutics (NYSE: CATX) will present clinical data on its [212Pb]VMT-α-NET program for advanced neuroendocrine tumors at the NANETS 2026 symposium. The company is developing radiopharmaceutical treatments using alpha-emitting isotopes to target cancer cells. Interim data was previously presented at the 2026 ASCO meeting, with additional data planned for future conferences. The company is also advancing other clinical-stage programs in the U.S.

quiverquant.com1 min